Findings showed nivolumab/relatlimab did not significantly improve recurrence-free survival compared with nivolumab monotherapy. A phase 3 trial evaluating nivolumab and relatlimab-rmbw (Opdualag ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback